在未接受华法林治疗的静脉血栓抗脂综合征患者中,直接口服抗凝剂的长期疗效和安全性:试点前性病例系列研究
Daniele Pastori1, Danilo Menichelli2, Gian Marco Podda3
1Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, Rome, 00161, Italy.
Journal of thrombosis and thrombolysis
|August 29, 2025
概括
直接口服抗凝剂 (DOACs) 对无法使用维生素K抗剂 (VKAs) 的静脉血栓塞 (VTE) 患者具有前景. 这项试点研究没有发现复发性静脉瘤或动脉事件,这表明DOAC可能是安全的替代品.
科学领域:
- 血液学
- 血栓形成研究
- 临床药理学
背景情况:
- 在静脉血栓抗脂抗体综合征 (APS) 中,有关直接口服抗凝剂 (DOAC) 的数据仍然存在争议.
- 维生素K抗剂 (VKA) 是标准的治疗方法,但有些APS患者不适合使用.
- 对于这一特定的患者群体,需要采用其他抗凝策略.
研究的目的:
- 在有静脉血栓栓塞 (VTE) 病史的APS患者中评估DOAC的安全性和有效性.
- 在不符合VKA治疗的患者中评估DOAC.
- 分析出血事件,血栓复发和死亡率.
主要方法:
- 未来,多中心案例系列设计.
- 包括18名先前患有VTE的APS患者,由于VKA资格不合格而接受DOAC治疗.
- 在平均随访时间为50. 1个月的时间里,监测出血事件,动脉血栓事件,复发性静脉动脉突发症和全因死亡.
主要成果:
- 在随访期间没有观察到复发性静脉动脉突发症或动脉血栓事件.
- 发生了四次出血事件,其中两次被归类为严重.
- 每 100 个患者年出血的发病率为 5. 3, 没有报告内出血.
结论:
- 初步发现表明DOAC可能是不适合VKAs的APS患者的可行治疗选择.
- 在这项试验中观察到的安全性和有效性是有希望的.
- 需要进行更大规模的队列研究来证实这些发现并制定最终的建议.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644


